SLCTR/2023/010尚未招募2 期
Efficacy and safety of deferoxamine, deferasirox, and deferiprone triple iron chelator combination therapy for transfusion-dependent beta-thalassaemia with very high iron overload
Prof Anuja Premawardhena0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female patients.
- •2.Transfusion-dependent beta-thalassemia major requiring at least eight transfusions per year.
- •3.Aged over 12 years.
- •4.Serum ferritin >3500ng/mL in the last two measurements done over the preceding 3-month.
- •5.Currently on combination therapy with deferoxamine and deferasirox.
排除标准
- •1.Pregnant and lactating females.
- •2.History of severe adverse effects to any of the three iron chelator chelators
- •3.Contraindications for any of the three iron chelators
研究者
相似试验
已完成
2 期
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCardiac Iron OverloadNCT01254227Novartis Pharmaceuticals60
Unknown
1 期
Deferoxamine and Xingnaojing Injection Treatment in Intracerebral HemorrhageIntracerebral HemorrhageNCT02367248Capital Medical University180
已完成
Unknown
Comparison of Deferazirox and Deferoxamine on Serum Ferritin Levels Changes in Major Beta Thalassemia PatientsIRCT20190817044550N4Birjand University of Medical Sciences45
已完成
2 期
Effect of Osveral on iron overload in beta thalassemia major patients.beta thalassemia.beta thalassemiaIRCT2015102524679N2Investigator69
已完成
2 期
Treatment of iron overload in thalassemia patientsThalassemia.Beta thalassaemiaIRCT2016041627412N1Vice Chancellor for research of Urmia University of Medical Sciences36